really really good, page-7

That’s a shock result for Ophthotech considering the really positive results it achieved in its large Phase 2 trial of Fovista. Coming on top of September’s announcement of failure in a Regeneron Phase 2 study, which tested Eylea in combination with another anti PGDF, it raises serious questions about the future of the anti VEGF-A +anti PGDF combination approach to the treatment of wet AMD.

This is doubtlessly also a shock result for Novartis, which in 2014 bet on Fovista in one of the largest ex-US agreements in biotech history. The potential value of that deal was $1 billion and included a $200 million upfront.

As already stated here, Opthotech’s failure will definitely put the spotlight on Opthea’s Phase 2a results, which are due to be announced before the end of March.

http://www.fiercebiotech.com/biotech/ophthotech-s-anti-pdgf-med-fails-late-stage-combo-tests-wet-amd

http://www.ophthotech.com/wp-content/uploads/Fovista_Fact_Sheet.pdf

http://www.streetinsider.com/Corpor...ge-Related Macular Degeneration/12087844.html